SCHEMBL4536620

SCHEMBL4536620

CC(=O)NC(c1cccc(Br)c1)C(O)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
CYP1A2 P05177 1/20 0.42
HSD17B10 Q99714 1/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
POLB P06746 1/20 0.39
S1PR4 O95977 1/20 0.38
S1PR3 Q99500 1/20 0.38
LMNA P02545 1/20 0.38
HIF1A Q16665 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
CTSA P10619 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PTGES O14684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8070685 0.82 SRC (0.47) ALDH1A1CYP1A2HSD17B10POLBLMNA
SCHEMBL7139715 0.82 SRC (0.47) ALDH1A1CYP1A2HSD17B10POLBLMNA
SCHEMBL4543253 0.82 ALDH1A1 (0.41) ALDH1A1CYP1A2HSD17B10MAPTL3MBTL1
SCHEMBL5021257 0.82 ALDH1A1 (0.41) ALDH1A1CYP1A2HSD17B10MAPTL3MBTL1
SCHEMBL13584745 0.82 ALDH1A1 (0.41) ALDH1A1CYP1A2HSD17B10MAPTL3MBTL1
SCHEMBL3893098 0.76 ALDH1A1 (0.59) ALDH1A1CYP1A2L3MBTL1POLBLMNA
SCHEMBL12341890 0.76 ALDH1A1 (0.59) ALDH1A1CYP1A2L3MBTL1POLBLMNA
SCHEMBL2769652 0.76 ALDH1A1 (0.59) ALDH1A1CYP1A2L3MBTL1POLBLMNA
SCHEMBL3881452 0.76 ALDH1A1 (0.59) ALDH1A1CYP1A2L3MBTL1POLBLMNA
SCHEMBL5856096 0.73 SRC (0.58) ALDH1A1MAPTLMNACTSA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49735-E1 Oxazolidinones as modulators of MGLUR5 BRISTOL-MYERS SQUIBB COMPANY (US) 2023-11-28 US disclosed
EP-2638022-B1 OXAZOLIDINONES AS MODULATORS OF MGLUR5 BRISTOL MYERS SQUIBB CO (US) 2014-12-24 EP disclosed
EP-2638022-A1 OXAZOLIDINONES AS MODULATORS OF MGLUR5 Bristol-Myers Squibb Company (US) 2013-09-18 EP disclosed
US-20120283264-A1 Oxazolidinones as Modulators of MGLUR5 BRISTOL-MYERS SQUIBB COMPANY 2012-11-08 US disclosed
WO-2012064603-A1 OXAZOLIDINONES AS MODULATORS OF MGLUR5 BRISTOL-MYERS SQUIBB COMPANY (US) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283264-A1 Oxazolidinones as Modulators of MGLUR5 GRM5, GRIK5, GRM1 ALDH1A1 3633/4885CYP1A2 3612/4885HSD17B10 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.